Aghajani,A , Khakpourian,Z , Bakhthiarzadeh,S , Adibipour,F , Sadr,M , Coleman-Fuller,N , Jamaati,H and Motaghinejad,M . (2023). Trimetazidine May Potentially Confer Neuroprotective Effects against COVID-19-Induced Neurological Sequelae via Inhibition of Death-Associated Protein Kinase 1 (DAPK1) Signaling Pathways: An Evidenced-Based Hypothesis. TANAFFOS (Respiration), 22(2), 182-186.

Aghajani,A , , Khakpourian,Z , , Bakhthiarzadeh,S , , Adibipour,F , , Sadr,M , , Coleman-Fuller,N , , Jamaati,H , and Motaghinejad,M . "Trimetazidine May Potentially Confer Neuroprotective Effects against COVID-19-Induced Neurological Sequelae via Inhibition of Death-Associated Protein Kinase 1 (DAPK1) Signaling Pathways: An Evidenced-Based Hypothesis", TANAFFOS (Respiration), 22, 2, 2023, 182-186.

Aghajani A, Khakpourian Z, Bakhthiarzadeh S, Adibipour F, Sadr M, Coleman-Fuller N, Jamaati H, Motaghinejad M. (2023). 'Trimetazidine May Potentially Confer Neuroprotective Effects against COVID-19-Induced Neurological Sequelae via Inhibition of Death-Associated Protein Kinase 1 (DAPK1) Signaling Pathways: An Evidenced-Based Hypothesis', TANAFFOS (Respiration), 22(2), pp. 182-186.

A Aghajani, Z Khakpourian, S Bakhthiarzadeh, F Adibipour, M Sadr, N Coleman-Fuller, H Jamaati and M Motaghinejad, "Trimetazidine May Potentially Confer Neuroprotective Effects against COVID-19-Induced Neurological Sequelae via Inhibition of Death-Associated Protein Kinase 1 (DAPK1) Signaling Pathways: An Evidenced-Based Hypothesis," TANAFFOS (Respiration), 22 2 (2023): 182-186,

Aghajani A, Khakpourian Z, Bakhthiarzadeh S, Adibipour F, Sadr M, Coleman-Fuller N, Jamaati H, Motaghinejad M. Trimetazidine May Potentially Confer Neuroprotective Effects against COVID-19-Induced Neurological Sequelae via Inhibition of Death-Associated Protein Kinase 1 (DAPK1) Signaling Pathways: An Evidenced-Based Hypothesis. TANAFFOS (Respiration). 2023;22(2):182-186.